Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-2.71% $64.67
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 7 072.05 mill |
EPS: | -0.910 |
P/E: | -71.07 |
Earnings Date: | Apr 24, 2024 |
SharesOutstanding: | 109.36 mill |
Avg Daily Volume: | 6.52 mill |
RATING 2024-04-18 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -71.07 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-12.09x |
Company: PE -71.07 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.575 (-99.11%) $-64.09 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 56.96 - 72.38 ( +/- 11.93%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Mancini Marianna | Buy | 31 667 | Common Stock, par value $0.00001 per share |
2024-03-27 | Mancini Marianna | Sell | 16 610 | Common Stock, par value $0.00001 per share |
2024-03-27 | Lian Brian | Buy | 221 667 | Common Stock, par value $0.00001 per share |
2024-03-27 | Lian Brian | Sell | 153 948 | Common Stock, par value $0.00001 per share |
2024-03-27 | Zante Greg | Buy | 31 667 | Common Stock, par value $0.00001 per share |
INSIDER POWER |
---|
10.02 |
Last 100 transactions |
Buy: 2 960 710 | Sell: 2 536 561 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $64.67 (-2.71% ) |
Volume | 2.38 mill |
Avg. Vol. | 6.52 mill |
% of Avg. Vol | 36.49 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $28.41 | N/A | Active |
---|
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.